Genscript Biotech Corporation provided earnings guidance for the year ended 31 December 2021. For the period, the Group is expected to record a loss of approximately $466.9 million to $518.6 million for the year ended 31 December 2021, as compared to a loss of approximately $281.4 million in 2020.